Agilent Technologies, Inc. (A)

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Ticker
A
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$50.00B
52-week range
$108.35 - $182.99

Valuation

Share price
$177.33 (close of Nov 18, 2026)
P/E (TTM)
34.77x
Price to book
6.79x
Price to free cash flow
39.46x
Enterprise value
$52.19B
Book value per share
$26.11

Price performance

PeriodChange
1 day+2.97%
5 days+0.21%
1 month+2.52%
3 months+19.46%
6 months+58.18%
Year to date+30.32%
1 year+23.28%
3 years+56.72%
5 years+9.35%
10 years+293.72%
All time+463.43%

Short interest

As of
Oct 30, 2026
Short % of float
1.97%
Shares short
4.89M
Days to cover
2.24
Change since prior report
-2.65%
Source
FINRA consolidated short interest

Members of Congress who disclosed A trades

Julie Johnson · Jefferson Shreve · Lisa McClain · Robert Bresnahan · Tommy Tuberville

Super investors holding A

Andreas Halvorsen (Viking Global Investors) · Lee Ainslie (Maverick Capital LTD) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · William Von Mueffling (Cantillon Capital Management LLC) · Greenhaven Associates (Greenhaven Associates Inc)

Profitability and growth

Return on equity
19.33%
Return on invested capital
13.34%
Return on assets
10.24%
Return on capital employed
14.25%
Gross margin
52.43%
Net margin
18.75%
EBITDA margin
25.43%
Revenue growth
6.73%
Net income growth
1.09%
Free cash flow growth
-16.10%

Cash flow and balance sheet

Free cash flow yield (TTM)
2.53%
Current ratio
2.05x
Net debt to EBITDA
1.08x

Latest reported year

Period end
Oct 31, 2025
Fiscal year
2025
Revenue
$6.95B
Cost of revenue
$3.31B
Gross profit
$3.64B
EBITDA
$1.77B
Net income
$1.30B
Earnings per share
$4.59
Research and development
$455.00M
Interest expense
$112.00M
Shares outstanding
284.00M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-10-31$6.95B$3.64B$1.30B$4.59
2024-10-31$6.51B$3.54B$1.29B$4.44
2023-10-31$6.83B$3.46B$1.24B$4.22
2022-10-31$6.85B$3.72B$1.25B$4.19
2021-10-31$6.32B$3.41B$1.21B$3.98
2020-10-31$5.34B$2.84B$719.00M$2.33
2019-10-31$5.16B$2.81B$1.07B$3.41
2018-10-31$4.91B$2.68B$316.00M$0.98
2017-10-31$4.47B$2.41B$684.00M$2.12
2016-10-31$4.20B$2.20B$462.00M$1.42

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-10-3152.43%18.75%19.33%13.34%
2024-10-3154.30%19.80%21.85%13.52%
2023-10-3150.71%18.15%21.21%14.58%
2022-10-3154.35%18.31%23.64%16.94%
2021-10-3153.92%19.15%22.45%14.42%
2020-10-3153.14%13.47%14.75%9.76%
2019-10-3154.33%20.74%22.56%13.15%
2018-10-3154.54%6.43%6.91%7.10%
2017-10-3153.87%15.30%14.15%10.05%
2016-10-3152.28%10.99%10.88%8.67%

Cash and debt by year

Period endCashDebt
2025-10-31$1.79B$3.05B
2024-10-31$1.33B$3.35B
2023-10-31$1.59B$2.73B
2022-10-31$1.05B$2.73B
2021-10-31$1.48B$2.73B
2020-10-31$1.44B$2.28B
2019-10-31$1.38B$1.79B
2018-10-31$2.25B$1.80B
2017-10-31$2.68B$1.80B
2016-10-31$2.29B$1.90B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-10-31$1.15B$128.00M
2024-10-31$1.37B$129.00M
2023-10-31$1.47B$111.00M
2022-10-31$1.02B$125.00M
2021-10-31$1.30B$110.00M
2020-10-31$802.00M$83.00M
2019-10-31$866.00M$72.00M
2018-10-31$910.00M$70.00M
2017-10-31$713.00M$60.00M
2016-10-31$654.00M$58.00M

Dividend history

Most recent payment
Oct 6, 2026
Paid in the last twelve months
$1.02
Payment dateDividend per share
2026-10-06$0.26
2026-06-30$0.26
2026-03-31$0.26
2026-01-06$0.26
2025-09-30$0.25
2025-07-01$0.25
2025-04-01$0.25
2024-12-31$0.25

Investor relations

Next earnings report

Next confirmed report
Nov 23, 2026
Consensus EPS estimate
$1.72

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-26Jul 2026$1.48
2026-05-27Apr 2026$1.40
2026-02-25Jan 2026$1.37
2025-11-24Oct 2025$1.59
2025-08-27Jul 2025$1.36
2025-05-28Apr 2025$1.26
2025-02-26Jan 2025$1.27
2024-11-25Oct 2024$1.41

Filings and sources

Company website
agilent.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

IQVIA Holdings Inc. (IQV) · Natera, Inc. (NTRA) · IDEXX Laboratories Inc (IDXX) · Danaher Corp (DHR) · Waters Corp (WAT) · Thermo Fisher Scientific Inc. (TMO) · Illumina, Inc. (ILMN) · Mettler-Toledo International Inc (MTD)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades